34 results about "Blepharitis" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

Disclosed herein are compositions which can be used in methods for treating or preventing ophthalmic and dermatologic conditions in a human subject, including ocular surface conditions such as blepharitis or rosacea. The compositions can be topically administered directly to an eye, eyelid, or eyelashes of the patient for targeted local activity.

Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting.

A new method of treating a skin disease or condition in a human subject caused by a parasite, particularly Demodex mite infestations that result in demodicosis, with moxidectin. The demodicosis is typically Demodex blepharitis.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

The invention belongs to the field of traditional Chinese medicine compositions, and relates to an external traditional Chinese medicine composition and preparation for treating demodex blepharitis, the traditional Chinese medicine composition comprises the following raw materials by weight: 3-10 parts of coptis chinensis, 3-10 parts of sophora flavescens, and 7.5-10 parts of saposhnicovia divaricata. According to the formula, coptis chinensis and radix sophorae flavescentis are used as monarch drugs for clearing away heat and drying dampness and killing parasites to relieve itching, and the pathogenesis core of demodex infection and damp-heat interweaving is adopted; divaricate saposhnikovia root is used as a ministerial drug to dispel wind and eliminate dampness, eliminate swelling and relieve itching and help the monarch drug to relieve wind pathogen symptoms such as red, swollen, itching and pain of eyelids. In addition, the radix saposhnikoviae is slightly warm in nature and flavor, has the function of adjuvant drugs in the formula, and moderately restricts the bitter and cold nature of the coptis chinensis and the radix sophorae flavescentis; the traditional Chinese medicine composition is an external preparation, no conductant drug is independently arranged in the whole formula, and the formula is further simplified on the premise that the curative effect is guaranteed. The whole formula directly aims at the pathological core of vermiform mite infection and inflammatory response through triple action mechanisms of clearing away heat and toxic materials, dispelling wind and eliminating dampness and killing parasites to relieve itching. The total effective rate of the traditional Chinese medicine composition for demodex blepharitis reaches 94%, and the traditional Chinese medicine composition has the advantages of stable curative effect, high total effective rate, low recurrence rate, small side effect and the like.

Provided herein are compositions for the prevention and treatment of demodex blepharitis in a subject and processes of treatment or prevention of demodex blepharitis. The compositions may include at least one avermectin compound selected from 5-O-demethyl-22,23-dihydroavermectin A1a or 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a, or a combination thereof, and melatonin, wherein an aggregate concentration of the avermectin compound is optionally less than 1 wt %. Further devices are provided that include wipe including a woven or non-woven membrane and a treatment composition, the treatment composition including melatonin, one or more anti-microbial compounds, and optionally one or more pharmaceutically acceptable excipients and processes of treatment or prevention of demodex blepharitis in a subject using the wipe, alone or optionally further with the composition as provided herein.

Disclosed are ophthalmic compositions for removing biofilms from the eye and for treating inflammation, blepharitis and dry eye of the eye, the ophthalmic compositions comprising an alpha-amylase and optionally other ingredients. The blepharitis is inflammation of eyelids and areas around the eyelids. The blepharitis generally affects both eyes, including areas along the edges of the eyelids. The blepharitis is considered to occur when tiny oil glands near the roots of the eyelashes become clogged, causing stimulation and redness. Several diseases and conditions may be associated with blepharitis.

To provide an ophthalmic agent and an ophthalmic antibacterial agent that contain azithromycin and are administered in specific doses and dosage regimens for specific indications.SOLUTION: The present invention relates to an ophthalmic agent that contains azithromycin and ophthalmologically acceptable additives to prevent or treat one or more of a patient's blepharitis, hordeolum, and lacrimal pouchitis or to prevent the progression of the disease, the ophthalmic agent being applied to the patient twice daily for 2 days and then once daily for 12 days in an appropriate quantity once. The invention also relates to an ophthalmic antibacterial agent.SELECTED DRAWING: None

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of the discomforts of dermatological disorders (e.g., diseases) The treatment is for the dysesthesia (e.g., caused by irritation, itch, or pain) due to dermatitis, urticaria; scalp itch; vulvar itch; lichen sclerosus; cholestatic itch; psoriasis; sebhorrheic dermatitis; allergic conjunctivitis; blepharitis; and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates the dysesthesia of these conditions in human subjects. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in the treatment of the dysesthesia of these dermatological disorders.

A heated eye mask apparatus for therapeutic treatment of meibomian gland dysfunction, blepharitis, dry eye disease, and related ocular conditions. The apparatus comprises a body portion with adjustable straps and a pair of detachable eye covers releasably secured to the body portion via fastening mechanisms enabling positional adjustment. Each eye cover includes at least one heating element with multiple independently controllable heating zones, allowing targeted thermal therapy to specific periocular anatomical regions. The heating elements are powered by rechargeable batteries integrated within the body portion, providing cordless operation. Flexible tethers connect the eye covers to the body portion, providing mechanical retention and electrical connectivity. A control interface comprising user-actuatable buttons enables independent activation of heating zones. Alternative embodiments may include a steam generation system providing combined heat and moisture therapy. The adjustable configuration accommodates varying facial anatomies and enables customized treatment based on individual therapeutic requirements.

An ophthalmic therapeutic treatment composition includes a topical cream containing a crosslinked acrylic acid polymer, an acrylamide / sodium acryloyldimethyl taurate copolymer, and an effective amount of an active pharmaceutical ingredient (API) dispersed in the topical cream. The ophthalmic therapeutic treatment composition and API are formulated for topical application and treatment of various disorders such as dry eye, presbyopia, intraocular pressure and blepharitis.

A topical composition comprising, as active ingredient, a mixture of hyaluronic acid, trehalose and an extract of roots of Ophiopogon japonicus, for use as soothing and / or moisturizing agent for the eyelids and / or the contour of the eye in a subject with sensitive skin, in particular with blepharitis.

Blepharitis, an infection and inflammation of the edge of the eyelids, and meibomian gland dysfunction (MGD), blockage of tiny oil glands at the eye lid margin, are quite common, usually under diagnosed and underappreciated diseases. There are number of causes for blepharitis, including bacterial components such as Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium acnes and Corynebacteria sp., seborrhea or microscopic mites (Demodex). More than 50% of patients seeking ophthalmologic consultations have symptoms and signs indicating one of these entities. Another large number of patients remain undiagnosed or in early stages of disease that could be easily treated thus preventing long-term pain and suffering. MGD is in fact the leading cause of dry eye disease, a potentially preventable malady.

Ophthalmic compositions for removing biofilms from the eye and for treating ocular inflammation, blepharitis, and dry eye are disclosed, comprising α-amylase, and optionally other ingredients.

The embodiment of the invention provides an eyelid margin inflammation detection device, an eyelid margin inflammation detection method, computing equipment and a computer program product. The eyelid margin inflammation detection device comprises an image generation module which is used for shooting a to-be-detected eyelid by using a cross polarization light source to generate an eyelid coronal plane image; the signal extraction module is used for performing hemoglobin signal extraction processing on the eyelid coronal plane image to obtain a to-be-detected image; the first detection module is used for dividing an eyelid detection area and an eyelid margin detection area in the to-be-detected image; the first identification module is used for identifying a first hemoglobin abnormal region and a second hemoglobin abnormal region; the first determination module is used for determining a first proportion and a second proportion; and the detection module is used for obtaining a detection result of the to-be-detected eyelid according to the first proportion and the second proportion. According to the technical scheme provided by the embodiment of the invention, the accuracy of blepharitis marginata inflammation detection is improved.

The invention relates to the field of pharmaceutical preparations, in particular to a preparation method and application of a stable nitroimidazole ophthalmic pharmaceutical composition. Specifically, the invention relates to an ophthalmic pharmaceutical composition, which comprises a nitroimidazole drug, a solubilizer, a stabilizer, a thickener, an osmotic pressure regulator and a pH regulator, and the stabilizer comprises a block polymer. The invention also relates to a preparation method of the ophthalmic pharmaceutical composition and application of the ophthalmic pharmaceutical composition in prevention / treatment of demodex blepharitis and meibomian gland dysfunction.

The present invention relates to mixtures, or compositions comprising said mixtures, comprising at least one bacterial strain, preferably at least one probiotic bacterial strain or a derivative thereof, as well as to the use of said mixtures or compositions in methods for the preventive and / or curative treatment of an inflammatory ocular and / or periocular lesion, preferably in methods for the treatment of ocular diseases such as dry eyes, eyelid allergy, conjunctivitis, blepharitis, meibonite, dacryoliths, stye, inflammatory lesions of ocular adnexa and associated symptoms.

The invention discloses a transdermal detumescence itching-relieving anti-fatigue eye patch and a preparation method thereof, the transdermal detumescence itching-relieving anti-fatigue eye patch comprises a transdermal patch and a transdermal agent, the transdermal agent is prepared by blending traditional Chinese medicine components and auxiliary materials, the traditional Chinese medicine components comprise honeysuckle flowers, wild chrysanthemum flowers, cassia seeds, rhizoma dioscoreae nipponicae, folium isatidis, mint, dandelions, spina gleditsiae, fructus cnidii, herba schizonepetae, radix saposhnikoviae, radix sophorae flavescentis, senecio scandens, cortex dictamni, pearl powder, borneol, selfheal and thunberg fritillary bulbs; the auxiliary material is yellow vaseline. The eye pad disclosed by the invention has the effects of clearing away heat and toxic materials, soothing the liver and promoting the circulation of qi, removing heat and dampness, softening hardness to dissipate stagnation, diminishing swelling and expelling pus, and eliminating dampness and relieving itching, and achieves the purposes of curing eyelid inflammation, relieving itching, resisting allergy and resisting fatigue.

To provide a composition for use in a method of treating an IL-4 / IL-13 related disorder.SOLUTION: Provided is a composition for use in a method of treating an eye-related disorder in a subject in need thereof with an anti-interleukin-4 receptor α (anti-IL-4Rα) antibody, wherein the eye-related disorder is selected from dry eye, blepharitis, cicatricial pemphigoid, Mooren's corneal ulcer, Vogt-Koyanagi-Harada syndrome, sympathetic ophthalmia, phacoanaphylaxis endophthalmitis, or a combination thereof, and wherein the method comprises administering a therapeutically effective amount of the anti-IL-4Rα antibody to the subject.SELECTED DRAWING: Figure 2

An ophthalmic liposomal product for use in a curative or preventive treatment of disorders or diseases of the eye and periocular area, comprises, or consists of, S75 Phospholipids, lactoferrin, Vitamin E TPGS, Stearylamine, EDTA and a viscosifier selected from the Poloxamer 407 / 188 family, is sterilizable by filtration at 0.2, is stable to aging, with pH between 7.0 and 7.5 and is provided with antibacterial activity which falls under efficacy criteria A, as prescribed by the European Pharmacopoeia F.I.XII. The lactoferrin liposomes with an amount of Stearylamine not exceeding 0.0030% of the total weight and 0.07-0.15% of Vitamin E TPGS % are obtained by extrusion at a pressure between 700 and 800 bar. The lactoferrin liposomes are present at 0.5% by weight on the total weight and the ratio between S75 phospholipids and lactoferrin is 1.5 / 0.5 = 3, sufficient for the lactoferrin to be totally encapsulated. The liposomes of lactoferrin, Stearylamine and Vitamin E TPGS have an electrical potential, measured in distilled water, using a particle analyzer by means of a light scattering technique (DLS), less than 0 mV so as to synergistically strengthen the abilities thereof in preventing and / or treating eye disorders, in particular those in which there is an inflammatory condition such as dry eye syndrome and the related complications, such as chalazion, stye (chronic chalazion), conjunctivitis, blepharitis and keratitis and reducing the possible aging of the lactoferrin protein.

The present invention relates to a sterile ophthalmic composition comprising castor oil and medium-chain triglycerides; to the use of said composition in medicine, in particular for the treatment and / or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, lax eye lid syndrome, thyroid eye disease, pterygium, conjunctival laxity, epithelial damage caused by preservatives, epithelial or anterior chamber damage caused by ocular surgery, corneal limbal cell deficiency, corneal ulceration caused by physical or chemical agents, keratitis, sub-scleritis and uveitis.

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for treating ocular diseases or conditions, including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. The compositions and methods comprise steroids and prostaglandins that exhibit anti-inflammatory activity, reduce intraocular pressure (IOP), and / or other desirable activities. Injection of the compositions in the eye provides therapeutic benefits to patients suffering from ocular conditions.

The present invention provides a Lotilaner-containing microemulsion eye drop, a preparation method therefor, and a use thereof in eye diseases such as demodex blepharitis, ocular rosacea, and meibomian gland dysfunction.

The invention relates to a method for constructing an aerogel solid drug delivery system for treating blepharitis, which belongs to the field of ophthalmic medical technology. The scheme is as follows: step 1, dissolving a polar drug in an ethanol solution to obtain solution A, adding a metal frame carrier to solution A, stirring, centrifuging, and drying to obtain a polar drug-metal frame delivery system; step 2, fully cross-linking the aerogel material, the polar drug-metal frame delivery system, and a cross-linking agent, adding a volatile oil component and stirring until there are no bubbles to obtain a mixed glue B; or fully cross-linking the aerogel material, the volatile oil component, and the cross-linking agent, stirring until there are no bubbles, breaking them into a thick liquid state, adding a polar drug-metal frame delivery system, and stirring evenly to obtain a mixed glue C; step 3, freeze-drying the mixed glue B or the mixed glue B to obtain an aerogel solid drug delivery system for treating blepharitis. The bactericidal effect of the present invention is significantly higher than that of traditional dressings.

This invention provides a semi-fluorinated alkane eye drop containing loteranal and its preparation method, as well as its application in eye diseases such as Demodex blepharitis, ocular erythema acne, and meibomian gland dysfunction.

Chondroitin sulfate-based pharmaceutical formulations useful for the treatment of ocular pain or discomfort, such as occurring from ocular surgery, dry eye disease, ocular surgery induced dry eye disease, contact lens induced ocular surface dry eye disease, preservative induced ocular surface disease, conjunctivitis, corneal abrasion, burns, blepharitis, and stye.